Laferon - instructions for use, doses, indications

Release form and composition

Dosage form of Laferon: freeze-dried powder (in ampoules or bottles, 1, 5 or 10 pieces in cardboard boxes; 1 or 5 ampoules or bottles complete with a solvent - water for injection, 1 set in a cardboard box).

The active substance is recombinant human interferon alpha-2b, its activity in 1 bottle or ampoule can be: 100 thousand International Units (IU), 1 million IU, 3 million IU, 5 million IU, 6 million IU, 9 million IU and 18 million ME.

Additional components: potassium dihydrogen phosphate, dextran, anhydrous sodium hydrogen phosphate, sodium chloride.

Indications for use

Laferon is recommended for use as part of combination therapy for adults and children for the following diseases:

Acute bacterial, viral and mixed infections;
Septic diseases in acute and chronic form, viral and bacterial etiology (including sepsis);
Acute and chronic viral hepatitis B (in moderate and severe form);
Herpetic infections of various localizations: herpes zoster, multiple herpetic rashes, herpetic keratoconjunctivitis and keratouveitis, genital infections;
Urogenital chlamydia in chronic form;
Lesions of the nervous system occurring with mono- and polyradicular pain syndromes;
Multiple sclerosis;
Laryngeal papillomatosis;
Hemoblastoses: hairy cell leukemia, chronic myeloid leukemia, malignant non-Hodgkin lymphoma;
Malignant tumors: melanoma of the skin and eye, multiple myeloma, Kaposi's sarcoma, cancer of the bladder, kidney, ovary, breast.

Use of the drug Laferon-farmbiotek powder for the preparation of solution for injection

Laferon-PharmBiotek solution is administered intramuscularly, subcutaneously, intravenously, endolymphatically, intraperitoneally, intravesically, rectally, parabulbarly, intranasally. For dissolution, water for injection is used if the contents of the bottle are dissolved in 1 ml, and saline solution if the contents of the bottle are dissolved in a larger volume. Acute viral hepatitis B:

1 million IU is administered intramuscularly (in severe cases, 2 million IU) 2 times a day for 10 days. Such a course can be extended to 2–3 weeks depending on the clinical status of the patient or continued at 1 million IU 2 times a week for several weeks.

Chronic viral hepatitis B:

administered intramuscularly at 3–4 million IU 3 times a week for 2 months.

Chronic viral hepatitis C:

administered intramuscularly at 3 million IU 3 times a week for 6 months as monotherapy or in combination with nucleoside analogues.

ARVI in children, including newborns:

administer 2–3 drops intranasally into each nasal passage 3–6 times a day for 3–5 days; dosage of the drug for newborns is 20–50 thousand IU/ml, for children over 6 months of age — 100 thousand IU/ml. It is acceptable to insert into the nasal passages (alternately) cotton wool moistened with Laferon-PharmBiotek for 10–15 minutes.

ARVI (including influenza) in adults:

1–3 million IU is administered intramuscularly, starting from the 1st–2nd day of illness for 3 days;
intranasally, 4–6 drops of Laferon-PharmBiotek solution (100 thousand IU/ml) into each nasal passage 6–8 times a day (before use, the administered dose of Laferon-PharmBiotek should be heated in a syringe (use a syringe without a needle) to temperature body, store the rest of the solution in the refrigerator, protecting it from bacterial contamination).

Acute and recurrent pneumonia of viral and viral-bacterial etiology:

Laferon-PharmBiotek is administered intramuscularly at a dose of 1 million IU for 5–7 days against the background of complex treatment, including antibacterial, detoxification, and anti-inflammatory therapy.

Acute diarrheal syndrome in newborns:

rectally in the form of daily microenemas containing 100 thousand IU of Laferon-PharmBiotek for 3–7 days.

Acute intestinal infections in young children with hypocoagulation symptoms:

rectally at a dose of 10 thousand IU/kg body weight 3 times with an interval of 48 hours.

Purulent-septic diseases, peritonitis, multiple abscesses of the abdominal cavity:

IV 2–4 million IU 1 time per day; total dose 12–16 million IU per course; the advisability of simultaneous endolymphatic administration of the drug in the same dose cannot be ruled out: 2–4 million IU once a day.

Herpetic infections: herpes zoster: daily 1 million IU IM + 2 million IU in 5 ml of physiological solution subcutaneously at several points around the rash area. Duration of treatment is 5–7 days. Skin herpetic rashes: daily intramuscular or subcutaneous injection (around the lesion) of the drug at a dose of 2 million IU; treatment can be combined with local application of the drug (applications) to herpetic papules. Genital herpetic infection: daily intramuscular administration at a dose of 2 million IU in combination with local application of the drug in the form of applications to the area of the rash. Herpetic keratoconjunctivitis: administration of Laferon-PharmBiotek solution at a dose of 1 million IU in 5 ml of physiological solution under the conjunctiva of the eye, 2-3 drops every 2 hours for 7-10 days; as the symptoms of the disease disappear, the drug can be dripped less frequently - every 4 hours. Chronic urogenital chlamydia: Treatment of patients with urogenital chlamydia is carried out in 2 stages: 1st stage - preparatory, which includes the use of enterosorbent, multivitamin preparations in therapeutic doses for 2 weeks. From the 10th day, the immunotropic drug Thymalin is prescribed, 10 mg IM in the evening every other day, for a course of 5 injections. Stage 2 is the main one, during which basic therapy with antibacterial agents is carried out according to the following scheme: the first antibiotic for 5 days; after a 7-day break, patients are prescribed another antibiotic for 10 days. During the break and after the end of the course of antibacterial therapy, Laferon-PharmBiotek is prescribed at a dose of 1 million IU IM once a day in the evening, a total of 10 injections per course. While taking antibacterial agents, it is necessary to use antifungal drugs (nystatin, diflucan, clotrimazole, nizoral) and hepatoprotectors (karsil) in therapeutic doses. Damage to the nervous system with mono- and polyradicular pain syndrome:

IM at a dose of 1 million IU, course 5–10 days with complex treatment.

Laryngeal papillomatosis:

intramuscularly (and, if possible, perifocally into the larynx) administration of Laferon-PharmBiotek at a dose of 100–150 thousand IU/kg body weight daily for 20–25 days. It is recommended to repeat such courses at intervals of 1–1.5 months for six months, and then after 2–3 months over the next six months. It is advisable to combine therapy with Laferon-PharmBiotek with the use of vitamin A (retinoids).

Multiple sclerosis:

1 million IU intramuscularly 2–3 times a day for 10–15 days, followed by 1 million IU once a week for six months.

Malignant tumors: skin melanoma: intramuscular administration of 3 million IU per day for 10 days, followed by repetition of these courses at intervals of 1.5 months for six months or: endolymphatic administration of Laferon-PharmBiotek 3 million IU 4 times with an interval of 48 h followed by endolymphatic administration of the drug monthly for 4 days, 1 million IU; uveal melanoma: parabulbar daily 1 million IU for 10 days; repeated 10-day administrations are carried out twice after 20 days; The general course of Laferon-PharmBiotek is 30 million IU. The need for repeated courses after 45 days is not excluded; treatment with Laferon-PharmBiotek is combined with photodestruction of the tumor and beta application; kidney cancer: IM daily for 10 days; dose - 3 million IU per injection; the total course is 30 million IU, repeated courses are carried out at intervals of 3–5 weeks for six months, and then at intervals of 1.5–2 months for a year; Bladder cancer: intravesical instillations at a dose of 5–10 million IU per instillation 3–6 times. The total course dose is 30 million IU. Repeat every 2–3 months for 1–2 years; ovarian cancer: intraperitoneally during surgery and in the next 5 days in the drainage, 5 million IU; further administration of Laferon-PharmBiotec - 3 million IU intramuscularly for 10 days between chemotherapy courses; The total dose of Laferon-PharmBiotec is 90 million IU. Subsequent courses can be prescribed at intervals of 2–3 months for 1–1.5 years: 3 million IU daily for 10 days; Breast cancer: IM daily for 10 days, 3 million IU per injection. Repeated courses are carried out throughout the year with an interval of 1.5–2 months, and then with an interval of 2–3 months (depending on the clinical status); it is advisable to alternate courses of therapy with Laferon-PharmBiotek with courses of chemotherapy (or radiation therapy); Kaposi's sarcoma: IM daily for 10 days, 3 million IU per injection; treatment is combined with monochemotherapy with prospidin; repeated courses - once a month for six months; multiple myeloma: IM daily for 10 days, 3 million IU per injection, repeated courses - once every 1.5-3 months (4-6 times during the year). Hemoblastoses: chronic myeloid leukemia: 5 million IU daily intramuscularly. Can be used as monotherapy or in combination with low doses of cytosar (Ara C) (20 mg/m2 per day every 10 days of the current month) and hydroxyurea (40 mg/m2 daily). The duration of the course is 6 months. When remission is achieved, maintenance therapy with Laferon-PharmBiotek at a dose of 5 million IU is carried out daily for up to 10–12 months; hairy cell leukemia: 3 million IU intramuscularly 3 times a week (every other day) for 4–6 weeks. When remission is achieved, maintenance therapy is carried out: 3 million IU every other day for up to 12 months; non-Hodgkin's malignant lymphoma: 3 million IU intramuscularly 3 times a week for 12–18 months as maintenance therapy upon achieving remission resulting from chemotherapy. During the period of partial remission, the use of other chemotherapy protocols with further therapy with Laferon-PharmBiotec 3 million IU intramuscularly 3 times a week for 18 months is indicated.

Directions for use and dosage

Laferon solution can be administered intravenously, subcutaneously, intramuscularly, intraperitoneally, endolymphally, intravesically, rectally, parabulbarly and intranasally. Water for injection is used as a solvent if the powder needs to be diluted in 1 ml, and isotonic sodium chloride solution (saline) if diluted in a larger volume is required.

The following dosage regimen is recommended:

Acute respiratory viral infection (ARVI). Children are prescribed 20-100 thousand IU/ml intranasally (depending on age), and it is also allowed to insert cotton wool pads soaked in the product into the nasal passages. Adults receive intramuscular injections in a dose of 1-3 million IU, or intranasal instillations - 4-6 drops 6-8 times a day;
Acute and recurrent pneumonia of viral-bacterial and viral etiology. It is recommended to administer intramuscularly at a dose of 1 million IU for 5-7 days as part of complex therapy;
Hepatitis B. Use intramuscularly for the acute form, 1 million 2 times a day for 10 days, for the chronic form - 3-4 million three times a week for 2 months;
Diarrheal syndrome of newborns. Administered rectally for 3-7 days (in the form of microenemas) 100 thousand IU per day;
Acute intestinal infections in children with hypocoagulation phenomena. Apply rectally at 10 thousand IU/kg body weight 3 times with an interval between doses of 2 days;
Purulent-septic diseases of the abdominal cavity. Prescribed intravenously at 2-4 million once a day, the total dose per course is 12-16 million IU;
Shingles. 2 million IU dissolved in 5 mg of saline is administered subcutaneously around the rash area daily, and 1 million IU intramuscularly for 5-7 days;
Skin herpetic rashes. Apply 2 million IU subcutaneously, injecting around the site of the rash;
Herpetic keratoconjunctivitis. Apply 2-3 drops of solution (1 million IU per 5 ml of saline) under the conjunctiva of the affected eye every 2 hours for 7-10 days;
Genital herpetic infection. 2 million IU is administered intramuscularly daily and applications are carried out on the rash area;
Laryngeal papillomatosis. They recommend intramuscular or (if possible) perifocal administration into the larynx at a dose of 100-150 thousand IU/kg body weight;
Multiple sclerosis. Take 1 million IU intramuscularly 3 times a day for 10-15 days, then at the same dose 1 time per week for 6 months;
Lesions of the nervous system, accompanied by poly- and monoradicular pain syndromes. 1 million IU is administered intramuscularly as part of a combination treatment for 5-10 days.

For the treatment of malignant tumors, the following doses of Laferon are recommended:

Breast cancer, skin melanoma, multiple myeloma, Kaposi's sarcoma: 3 million IU per day intramuscularly, 10 days;
Kidney cancer: 1 million IU intramuscularly, 10 days;
Uveal melanoma: 1 million IU daily parabulbar for 10 days;
Bladder cancer: 5-10 million IU in the form of intravesical instillations 3 to 6 times. The course is 30 million IU;
Ovarian cancer: 5 million IU intraperitoneally during surgery and during the subsequent 5 days - into the drainage. Subsequently, 3 million IU is prescribed intramuscularly for 10 days between chemotherapy courses, the total dose of the drug is 90 million IU.

Laferon-Farmbiotek nasal por-to-liof., for preg. nasal drops 1000000IU bottle No. 1

LAFERON - PharmBiotech NASAL International nonproprietary name: Interferon alfa-2b. General characteristics Lyophilized powder or porous mass, white, hygroscopic. Composition of the drug Active ingredient: recombinant human interferon alpha-2b. The vial contains 1 million International Units (IU) of interferon. Excipients: sodium chloride, dextran 70, potassium dihydrogen phosphate, anhydrous disodium hydrogen phosphate.

Dosage form: Lyophilisate for the preparation of nasal drops. Pharmacotherapeutic group: Immunostimulants. Interferon alpha-2b.

Indications for use LAFERON - PharmBiotek NASAL is used for: - treatment and prevention of acute respiratory viral and viral-bacterial infections in adults and children, including newborns. For the purpose of prevention, the drug is used when there is a threat of infection (during an epidemic period, in contact with a patient with an acute respiratory viral infection). For therapeutic purposes, the drug should be used as early as possible - at the first signs of the disease. The earlier its use is started, the higher the effectiveness of the drug.

Method of administration and dosage: Open the bottle with the dry powder of the drug and fill it with boiled water cooled to room temperature (from 15C to 25C). The top level of the liquid should be 1.0 cm below the opening of the bottle. Carefully close the bottle with a rubber stopper and, using gentle oscillating movements, completely dissolve the powder. Replace the rubber plug with the supplied dropper cap. The drops are ready for use. After each use of the drug, close the dropper with a protective cap. After filling the bottle, 1 ml of the prepared solution contains about 200 thousand IU of interferon. The most effective way to treat influenza and ARVI is inhalation. To carry it out, it is recommended to use inhalers-nebulizers. For inhalation use through a nebulizer, dissolve the drug in 3 ml of physiological solution, use for children at the rate of 25-30 thousand IU/kg per day, for adults - 500 thousand - 1 million IU (in 3 divided doses). To treat influenza and other respiratory viral infections, LAFERON-PharmBiotek NASAL drops are instilled into the nose every 2 hours in the following doses: infants - 2 drops 8 times a day; children from 1 to 7 years old - 4-6 drops 8 times a day; children over 7 years old - 8 drops 8 times a day; adults - 10-12 drops 8-10 times a day. Typically, the course of antiviral treatment with LAFERON - PharmBiotek NASAL is 3-5 days. For the purpose of prevention, LAFERON - PharmBiotek NASAL is used 4 drops 4 times a day.

Side effects Short courses of treatment with interferon in the form of nasal drops do not cause any side effects.

Contraindications Established allergy to interferon and excipients of the drug.

Overdose There were no cases of acute overdose of the drug.

Special instructions To preserve the immunobiological activity of the drug, only water cooled to room temperature (from 15C to 25C) should be used to dissolve the powder.

Use during pregnancy and breastfeeding The drug has not been studied in pregnant women and nursing mothers.

Interaction with other drugs Interferon alfa-2b can reduce the activity of P-450 cytochromes and thereby influence the metabolism of cimetidine, phenytoin, chimes, theophylline, diazepam, propranolol, warfarin, and some cytostatics. As a result, the neurotoxic, myelotoxic or cardiotoxic effects of these drugs may be enhanced. Caution should be used simultaneously with narcotic, sleeping pills and sedatives. Interferons can influence oxidative metabolic processes. This should be taken into account when used simultaneously with drugs that are metabolized by oxidation (including xanthine derivatives - aminophylline and theophylline). When used simultaneously with theophylline, it is necessary to monitor the concentration of the latter in the blood serum and, if necessary, adjust the dosage regimen. There are no data on negative interactions during complex therapy.

Storage conditions Store at a temperature from 2 C to 8 C in a place protected from light. Keep out of the reach of children. After opening the bottle and preparing the solution, store the drug for 5 days in the refrigerator or 2 days at room temperature (from 15 C to 25 C). The prepared solution should be protected from direct sunlight.

Shelf life: 3 years.

Conditions of release Without a doctor's prescription.

Packaging Bottles made of neutral transparent glass, sealed with a rubber stopper and closed with an aluminum cap or an aluminum cap with a colored plastic lining. 1 bottle in a cardboard box along with a plastic dropper cap with a protective cap in a protective shell. Instructions for use are included in the box.

Side effects

When injecting Laferon, especially at the beginning of the course, the following may often be observed: lethargy, chills, joint pain, increased body temperature, muscle pain and headache. During further treatment, these effects weaken and disappear, and they can also be stopped or significantly reduced by taking 0.5-1 g of paracetamol 30-40 minutes before the injection. With prolonged use, leukopenia and thrombocytopenia may develop, which can be eliminated by lowering the dose.

Symptoms of overdose may include prostration, deep disturbances of consciousness, and lethargy. These conditions are reversible and regress when the drug is discontinued.